NO20090610L - Faste preparater omfattende tadalafil og minst en baerer - Google Patents
Faste preparater omfattende tadalafil og minst en baererInfo
- Publication number
- NO20090610L NO20090610L NO20090610A NO20090610A NO20090610L NO 20090610 L NO20090610 L NO 20090610L NO 20090610 A NO20090610 A NO 20090610A NO 20090610 A NO20090610 A NO 20090610A NO 20090610 L NO20090610 L NO 20090610L
- Authority
- NO
- Norway
- Prior art keywords
- tadalafil
- carrier
- pharmaceutical compositions
- compositions
- solid preparations
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title abstract 3
- IEHKWSGCTWLXFU-IIBYNOLFSA-N tadalafil Chemical compound C1=C2OCOC2=CC([C@@H]2C3=C([C]4C=CC=CC4=N3)C[C@H]3N2C(=O)CN(C3=O)C)=C1 IEHKWSGCTWLXFU-IIBYNOLFSA-N 0.000 title abstract 3
- 229960000835 tadalafil Drugs 0.000 title abstract 3
- 239000007787 solid Substances 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 3
- 229940123333 Phosphodiesterase 5 inhibitor Drugs 0.000 abstract 2
- 238000004090 dissolution Methods 0.000 abstract 2
- 239000002590 phosphodiesterase V inhibitor Substances 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000008203 oral pharmaceutical composition Substances 0.000 abstract 1
- 239000008247 solid mixture Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Gynecology & Obstetrics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US81921506P | 2006-07-07 | 2006-07-07 | |
| PCT/US2006/043664 WO2008005039A1 (fr) | 2006-07-07 | 2006-11-09 | Compositions solides comprenant du tadalafil et au moins un véhicule |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20090610L true NO20090610L (no) | 2009-02-09 |
Family
ID=37733988
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20090610A NO20090610L (no) | 2006-07-07 | 2009-02-09 | Faste preparater omfattende tadalafil og minst en baerer |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20080009502A1 (fr) |
| EP (1) | EP1875914A1 (fr) |
| JP (1) | JP2009542648A (fr) |
| KR (1) | KR101140110B1 (fr) |
| CN (1) | CN101500572B (fr) |
| BR (1) | BRPI0621852A2 (fr) |
| CA (1) | CA2654902A1 (fr) |
| IL (1) | IL196272A0 (fr) |
| MX (1) | MX2008016569A (fr) |
| NO (1) | NO20090610L (fr) |
| RU (1) | RU2009103660A (fr) |
| WO (1) | WO2008005039A1 (fr) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20100012867A (ko) | 2007-04-25 | 2010-02-08 | 테바 파마슈티컬 인더스트리즈 리미티드 | 타다라필을 포함하는 고체 제형 |
| DE102007028869A1 (de) | 2007-06-22 | 2008-12-24 | Ratiopharm Gmbh | Verfahren zur Herstellung eines Arzneimittels enthaltend Tadalafil |
| EP2238979A1 (fr) | 2009-04-06 | 2010-10-13 | LEK Pharmaceuticals d.d. | Ingrédient pharmaceutique actif absorbé sur un support solide |
| DE102009033396A1 (de) | 2009-07-16 | 2011-01-20 | Ratiopharm Gmbh | Wässrige Lösung und gelatinierte Zusammensetzung umfassend einen Phosphodiesterase-5-Inhibitor sowie diesbezügliche Verfahren und Verwendung |
| DE102009035211A1 (de) * | 2009-07-29 | 2011-02-17 | Ratiopharm Gmbh | Copräzipitate umfassend einen Phosphodiesterase-5-Inhibitor (PDE-5-Inhibitor) und einen pharmazeutisch verträglichen Trägerstoff, ihre Herstellung und Verwendung |
| WO2011030351A2 (fr) | 2009-09-03 | 2011-03-17 | Rubicon Research Private Limited | Compositions pharmaceutiques au goût masqué |
| US10610528B2 (en) * | 2009-12-08 | 2020-04-07 | Intelgenx Corp. | Solid oral film dosage forms and methods for making same |
| US20110136815A1 (en) * | 2009-12-08 | 2011-06-09 | Horst Zerbe | Solid oral film dosage forms and methods for making same |
| US20110263606A1 (en) * | 2010-04-26 | 2011-10-27 | Horst Zerbe | Solid oral dosage forms comprising tadalafil |
| WO2012085927A2 (fr) * | 2010-12-02 | 2012-06-28 | Mylan Laboratories, Limited | Compositions de tadalafil |
| WO2012095151A1 (fr) | 2010-12-23 | 2012-07-19 | Zaklady Farmaceutyczne Polpharma Sa | Formes pharmaceutiques solides comprenant du tadalafil et ses procédés de préparation |
| WO2012107541A1 (fr) | 2011-02-10 | 2012-08-16 | Synthon Bv | Composition pharmaceutique comprenant du tadalafil et une cyclodextrine |
| EP2672959A1 (fr) | 2011-02-10 | 2013-12-18 | Synthon BV | Composition de granulés comportant du tadalafil et un délitant |
| WO2012107092A1 (fr) | 2011-02-10 | 2012-08-16 | Synthon Bv | Composition pharmaceutique comportant du tadalafil et une cyclodextrine |
| CN103998043B (zh) * | 2011-12-26 | 2016-09-21 | 群泰生物科技股份有限公司 | 促进第五型磷酸二酯酶抑制剂经皮吸收的方法及医药组合物 |
| WO2014003677A1 (fr) * | 2012-06-28 | 2014-01-03 | Xspray Microparticles Ab | Compositions pharmaceutiques comprenant des particules de dispersion solide contenant du tadalafil |
| WO2014003678A1 (fr) * | 2012-06-28 | 2014-01-03 | Xspray Microparticles Ab | Compositions pharmaceutiques comprenant de l'ambrisentan et des particules de dispersion solide contenant du tadalafil |
| WO2014027979A2 (fr) | 2012-08-17 | 2014-02-20 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Formulations de comprimés comprenant du tadalafil et de la dapoxétine |
| WO2014027982A2 (fr) | 2012-08-17 | 2014-02-20 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Nouvelles formulations de sachets effervescents de dapoxétine et d'un inhibiteur de pde5 |
| US20150320677A1 (en) | 2012-08-17 | 2015-11-12 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Effervescent tablet formulations of dapoxetine and a pde5 inhibitor |
| US20160000720A1 (en) * | 2013-02-14 | 2016-01-07 | Aurobindo Pharma Limited | Pharmaceutical compositions comprising Tadalafil |
| WO2015000853A1 (fr) * | 2013-07-05 | 2015-01-08 | Synthon B.V. | Composition pharmaceutique comprenant une dispersion solide de tadalafil |
| CN104188912B (zh) * | 2014-07-17 | 2017-12-22 | 山东大学 | 他达拉非固体分散体及其片剂 |
| EA035390B1 (ru) | 2014-07-23 | 2020-06-05 | КРКА, д.д., НОВО МЕСТО | Совместный осадок тадалафила с фармацевтически приемлемыми эксципиентами, содержащая его фармацевтическая композиция и способ их получения |
| KR101712524B1 (ko) * | 2014-08-21 | 2017-03-08 | 동국제약 주식회사 | 타달라필 및 두타스테라이드를 포함하는 복합제제 조성물 및 그 제조방법 |
| KR101538985B1 (ko) * | 2014-09-02 | 2015-07-24 | 주식회사 서울제약 | 타다라필 구강붕해필름 및 이의 제조방법 |
| KR20160138796A (ko) | 2015-05-26 | 2016-12-06 | 삼아제약 주식회사 | 타달라필을 유효성분으로 함유하는 신규한 속효성 세립제형 |
| KR101634382B1 (ko) | 2015-10-20 | 2016-06-28 | 미래제약 주식회사 | 타다라필 경구용 액제 |
| WO2017104862A1 (fr) * | 2015-12-16 | 2017-06-22 | 동국제약 주식회사 | Composition de préparation composite comprenant du tadalafil et du dutastéride et son procédé de préparation |
| CN107303284A (zh) * | 2016-04-25 | 2017-10-31 | 湖北生物医药产业技术研究院有限公司 | 制备他达拉非片剂的方法及他达拉非片剂 |
| US10500202B2 (en) * | 2016-11-30 | 2019-12-10 | Druggability Technologies Ip Holdco Limited | Pharmaceutical formulation containing tadalafil |
| CN107334736A (zh) * | 2017-07-21 | 2017-11-10 | 广州中医药大学 | 他达拉非固体分散体系及其制备方法 |
| CN110812336B (zh) * | 2018-08-07 | 2021-09-10 | 迪沙药业集团有限公司 | 一种他达拉非片剂组合物 |
| KR102195162B1 (ko) | 2019-01-30 | 2020-12-24 | 단국대학교 천안캠퍼스 산학협력단 | 타다라필 함유 고체분산체 및 이의 제조방법 |
| WO2021145831A1 (fr) * | 2020-01-16 | 2021-07-22 | Pharmacti̇ve İlaç Sanayi̇ Ve Ti̇caret A.Ş. | Compositions pharmaceutiques comprenant du tadalafil et des excipients appropriés |
| KR20220057077A (ko) | 2020-10-29 | 2022-05-09 | 대화제약 주식회사 | 타다라필을 포함하는 구강붕해 필름 제형 |
| CN117042757A (zh) * | 2020-12-31 | 2023-11-10 | 东国制药株式会社 | 表现出新溶出速率的包含他达拉非或其药学上可接受的盐和度他雄胺或其药学上可接受的盐的药物组合物 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU171662B (hu) * | 1975-07-18 | 1978-02-28 | Richter Gedeon Vegyeszet | Sposob poluchenija novykh, opticheski aktivnykh proizvodnykh apovinkaminola i ikh kislotnykh adduktov |
| CA1146866A (fr) * | 1979-07-05 | 1983-05-24 | Yamanouchi Pharmaceutical Co. Ltd. | Procede de production d'un compose pharmaceutique a liberation continue sous forme solide |
| GB9401090D0 (en) * | 1994-01-21 | 1994-03-16 | Glaxo Lab Sa | Chemical compounds |
| GB9511220D0 (en) * | 1995-06-02 | 1995-07-26 | Glaxo Group Ltd | Solid dispersions |
| GB9514464D0 (en) * | 1995-07-14 | 1995-09-13 | Glaxo Lab Sa | Medicaments |
| US20040014761A1 (en) | 1997-10-28 | 2004-01-22 | Place Virgil A. | Treatment of female sexual dysfunction with phosphodiesterase inhibitors |
| AU4491200A (en) * | 1999-08-03 | 2001-02-19 | Lilly Icos Llc | Beta-carboline pharmaceutical compositions |
| US6821975B1 (en) * | 1999-08-03 | 2004-11-23 | Lilly Icos Llc | Beta-carboline drug products |
| ATE297196T1 (de) * | 1999-12-20 | 2005-06-15 | Nicholas J Kerkhof | Verfahren zur herstellung von nanometer partikeln durch fliessbett- sprühtrocknung |
| DK1471890T3 (da) * | 2002-02-07 | 2007-01-08 | Pharmacia Corp | Farmaceutisk doseringsform til mukös afgivelse |
| US20050019641A1 (en) * | 2003-06-18 | 2005-01-27 | Toshiyuki Aoyama | Fuel tank for fuel-cell and fuel cell system |
| US20050096418A1 (en) | 2003-10-31 | 2005-05-05 | Baranek Todd M. | High density metal oxide fillers in rubber compounds |
| AU2004311869A1 (en) | 2003-12-29 | 2005-07-21 | Michael Davis | Compositions and methods to treat recurrent medical conditions |
| US20050196418A1 (en) * | 2004-03-04 | 2005-09-08 | Yu Ruey J. | Bioavailability and improved delivery of alkaline pharmaceutical drugs |
| US20060276442A1 (en) * | 2004-09-08 | 2006-12-07 | Woodward John R | Methods of female sexual enhancement |
| US8367105B2 (en) * | 2004-11-10 | 2013-02-05 | Teva Pharmaceutical Industries, Ltd. | Compressed solid dosage form manufacturing process well-suited for use with drugs of low aqueous solubility and compressed solid dosage forms made thereby |
| DE102005016981A1 (de) * | 2005-04-13 | 2006-10-19 | Bayer Healthcare Ag | Kombination zur Therapie bei benigner Prostatahyperplasie |
| US20070009589A1 (en) * | 2005-07-07 | 2007-01-11 | Kandarapu Raghupathi | Extended release compositions |
| KR20100012867A (ko) * | 2007-04-25 | 2010-02-08 | 테바 파마슈티컬 인더스트리즈 리미티드 | 타다라필을 포함하는 고체 제형 |
-
2006
- 2006-11-09 BR BRPI0621852-0A patent/BRPI0621852A2/pt not_active IP Right Cessation
- 2006-11-09 WO PCT/US2006/043664 patent/WO2008005039A1/fr not_active Ceased
- 2006-11-09 KR KR1020097000700A patent/KR101140110B1/ko not_active Expired - Fee Related
- 2006-11-09 JP JP2009518090A patent/JP2009542648A/ja active Pending
- 2006-11-09 US US11/595,481 patent/US20080009502A1/en not_active Abandoned
- 2006-11-09 RU RU2009103660/15A patent/RU2009103660A/ru unknown
- 2006-11-09 CN CN2006800551991A patent/CN101500572B/zh not_active Expired - Fee Related
- 2006-11-09 CA CA002654902A patent/CA2654902A1/fr not_active Abandoned
- 2006-11-09 EP EP06255751A patent/EP1875914A1/fr not_active Withdrawn
- 2006-11-09 MX MX2008016569A patent/MX2008016569A/es not_active Application Discontinuation
-
2008
- 2008-12-30 IL IL196272A patent/IL196272A0/en unknown
-
2009
- 2009-02-09 NO NO20090610A patent/NO20090610L/no not_active Application Discontinuation
- 2009-12-23 US US12/646,733 patent/US20100099687A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| KR20090021380A (ko) | 2009-03-03 |
| MX2008016569A (es) | 2009-01-30 |
| JP2009542648A (ja) | 2009-12-03 |
| CN101500572B (zh) | 2013-08-21 |
| CN101500572A (zh) | 2009-08-05 |
| BRPI0621852A2 (pt) | 2011-12-20 |
| US20080009502A1 (en) | 2008-01-10 |
| US20100099687A1 (en) | 2010-04-22 |
| IL196272A0 (en) | 2009-09-22 |
| EP1875914A1 (fr) | 2008-01-09 |
| RU2009103660A (ru) | 2010-08-20 |
| CA2654902A1 (fr) | 2008-01-10 |
| WO2008005039A1 (fr) | 2008-01-10 |
| KR101140110B1 (ko) | 2012-06-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20090610L (no) | Faste preparater omfattende tadalafil og minst en baerer | |
| NO20084256L (no) | DPP IV inhibitorformuleringer | |
| TN2010000203A1 (en) | Beta-lactamase inhibitors | |
| UA99284C2 (ru) | ИНГИБИТОРЫ р70 S6-КИНАЗЫ | |
| TW200744665A (en) | Vitamin E succinate stabilized pharmaceutical compositions, methods for the preparation and the use thereof | |
| NO20070785L (no) | Sammensetninger for levering av svaert vannloselige medikamenter. | |
| ATE555786T1 (de) | 1-alkoxy 1h-imidazo-ringsysteme und verfahren | |
| IL229136A0 (en) | mek inhibitors and methods of using them | |
| MY143795A (en) | Tetrahydropyridoindole derivatives | |
| WO2007149406A8 (fr) | Polypeptides facteurs ix de la coagulation modifiés et leur utilisation thérapeutique | |
| IL184898A0 (en) | Pyrrolopyrimidine derivatives and pharmaceutical compositions containing the same | |
| WO2006026760A3 (fr) | Composes renfermant un 1-amino imidazo et procedes | |
| MX2009002772A (es) | Uso de 2-6-(3-amino-piperidin-1-il)-3-metil-2,4-dioxo-3,4-dihidro- 2h-pirimidin-1-ilmetil-4-fluoro-benzonitrilo. | |
| UY30942A1 (es) | Nuevos derivados de 3-([1,2,4,]triazolo[4,3-a]piridin-7-il)benzamida | |
| TNSN08178A1 (en) | Triazolopyridine derivatives as inhibitors of lipases and phospholipases | |
| CA2668320A1 (fr) | Utilisation de 3-alpha-androstanediol, eventuellement en combinaison avec un agoniste 5-ht1a, dans le traitement du dysfonctionnement sexuel | |
| WO2007146124A3 (fr) | Inhibiteurs de pde5 substitué | |
| MX2009000482A (es) | Compuestos terapeuticos. | |
| MX2009014235A (es) | 4-bencilaminoquinolonas, composiciones farmaceuticas que las contiene y su uso. | |
| UA97795C2 (uk) | Дейтеровані похідні катехоламіну і медикаменти, що містять згадані сполуки | |
| DK1641803T3 (da) | Thienopyrimidinderivater som kaliumkanalinhibitorer | |
| MX2009004017A (es) | Usos de los compuestos carboxi-amido triazol y sus sales. | |
| CL2008002082A1 (es) | Compuestos derivados de 6-fenil-1h-imidazo[4,5-c]piridina-4-carbonitrilo, inhibidores de catepsina s y catepsina k; composicion farmaceutica; y uso en el tratamiento de osteoporosis, aterosclerosis, inflamacion, entre otras enfermedades. | |
| NZ588428A (en) | Oral and injectable formulations of the tetracycline compound 9-[(2,2-dimethyl-propylamino)-methyl]-minocycline | |
| NO20062878L (no) | Isoflavonoidpromedikamenter, terapeutiske sammensetninger derav og terapeutiske fremgangsmater som innbefatter de samme |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |